MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024 [Seeking Alpha]
MacroGenics, Inc. (MGNX)
Last macrogenics, inc. earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.macrogenics.com
Company Research
Source: Seeking Alpha
Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » MacroGenics NASDAQ: MGNX ) is an important biotech to keep an eye on, because it has been able to make remarkable progress on advancing the use of its lead drug vobra duo [vobramitamab duocarmazine] in the ongoing phase 2 TAMARACK study for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC]. It just announced a key finding that may benefit it when it reports data at two time points later this year. It noted that there was a reduced rate of discontinuation of patients in this TAMARACK study for those who were given lower doses of 2 mg/kg and 2.7 mg/kg of vobra duo
Show less
Read more
Impact Snapshot
Event Time:
MGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGNX alerts
High impacting MacroGenics, Inc. news events
Weekly update
A roundup of the hottest topics
MGNX
News
- MacroGenics, Inc. (NASDAQ: MGNX) is now covered by analysts at B. Riley. They set a "buy" rating and a $25.00 price target on the stock.MarketBeat
- Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair [Yahoo! Finance]Yahoo! Finance
- We're Hopeful That MacroGenics (NASDAQ:MGNX) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- MacroGenics, Inc. (NASDAQ: MGNX) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating.MarketBeat
- ARCA biopharma, Achilles Therapeutics, MSP Recovery among healthcare movers [Seeking Alpha]Seeking Alpha
MGNX
Earnings
- 11/6/23 - Beat
MGNX
Sec Filings
- 4/8/24 - Form 4
- 4/8/24 - Form ARS
- 4/8/24 - Form DEFA14A
- MGNX's page on the SEC website